References
- Hoeper MM, Bedesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490.
- Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204–1215. DOI:10.1056/NEJMoa2024277.
- Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensions: identification of the most accurate estimates from a systemic literature review. Pulm Circ. 2021;11:2045894020977300. DOI: 10.1177/2045894020977300.
- Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887. DOI:10.1183/13993003.01887-2018.
- Southgate L, Machado RD, Gräf S, et al. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85–95. DOI:10.1038/s41569-019-0242-x.
- Joshi SR, Liu H, Bloom T, et al. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022;12:7803.
- Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension period. Eur Respir J. 2023;61(1):2201347. DOI:10.1183/13993003.01347-2022.
- Hoeper MM, Pausch C, Olsson KM, et al. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: a COMPERA analysis. J Heart Lung Transplant. 2022;41(7):971–981. DOI:10.1016/j.healun.2022.03.011.
- ClinicalTrials.gov. A long-term follow-up study of sotatercept for PAH treatment (MK-7962-004); SOTERIA. [cited 2023 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04796337?term=sotatercept&draw=2&rank=1
- ClinialTrials.gov. A study of sotatercept in participants with PAH WHO FC III or FC IV at high risk of mortality (MK-7962-006/ZENITH); ZENITH. [cited 2023 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04896008?term=sotatercept&draw=2&rank=2
- ClinialTrials.gov. Study of sotatercept in newly diagnosed intermediate- and high-risk PAH participants (MK-7962-005/A011-13); HYPERION. [cited 2023 Mar 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04811092?term=sotatercept&draw=2&rank=7
- Zijlstra WMH, Douwes JM, Rosenzweig ER, et al. Survival differences in pediatric pulmonary arterial hypertension. Clues to a better understanding of outcome and optimal strategies. J Am Coll Cardiol. 2014;63:2159–2169. DOI:10.1016/j.jacc.2014.02.575.
- ClinialTrials.gov. Study to evaluate sotatercept (MK-7962) in children with pulmonary arterial hypertension (PAH) (MK-7962-008); [cited 2023 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT05587712?term=sotatercept&draw=3&rank=19
- Joshi SR, Atabay EK, Liu J, et al. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure. Front Cardiovasc Med. 2023;10:1064290.
- ClinialTrials.gov. A study of sotatercept for the treatment of Cpc-PH due to HFpEF (MK-7962-007/A011-16); CADENCE. [cited 2023 Mar 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04945460?term=sotatercept&draw=2&rank=4
- Doggrell SA, Chan V. Adherence to insulin treatment in diabetes: can it be improved? J Diabetes. 2015;7:315–321.